D-0735-2026 Class III Ongoing
FDA drug recall D-0735-2026 was initiated by Ascend Laboratories, LLC on Jun 30, 2026 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month… The recall status is ongoing. Affected quantity: 1,753 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 29, 2026
- Initiation Date
- Jun 30, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,753 cartons
Product description
Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7254-68.
Reason for recall
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
Distribution pattern
USA Nationwide
Code information
Lot: 25141707, Exp 4/30/2027.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0735-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026